Nanjing-headquartered Immunophage Biotech Co., Ltd., a targeted therapy developer with operations in China, Australia, and the US, has announced a comprehensive partnership with Shanghai GoBroad Cancer Hospital and China Pharmaceutical University. The collaboration, which follows their initial alliance in December of last year regarding IPG7236, is focused on the Phase II clinical study for IPG1094. The study will be led by Professor Li Jin, Dean, Chief Scientist, and Chief Physician of Shanghai GoBroad Cancer Hospital, who will serve as the Principal Investigator (PI).
IPG1094: A First-in-Class MIF Inhibitor
IPG1094 is the world’s first small molecule MIF (Macrophage Migration Inhibitory Factor) inhibitor to enter clinical trials. The drug works by blocking the formation of MDSCs (Myeloid-Derived Suppressor Cells) and canceling their inhibitory effect on effector T cells, thereby restoring the anti-tumor immune response. As a broad-spectrum anti-tumor drug, IPG1094 is currently undergoing regulatory Phase II clinical trials in the United States and China, with the initial indication being brain metastasis of lung cancer.
Significance of the Partnership
This partnership underscores Immunophage’s commitment to advancing innovative cancer therapies through strategic collaborations. With the expertise of Professor Li Jin and the resources of Shanghai GoBroad Cancer Hospital, the Phase II study for IPG1094 is poised to provide valuable insights into the drug’s potential as a novel treatment option for patients with brain metastasis of lung cancer.-Fineline Info & Tech
